       Document 0866
 DOCN  M9550866
 TI    Modulation of interferon-mediated inhibition of human immunodeficiency
       virus type 1 by Tat.
 DT    9505
 AU    Shirazi Y; Popik W; Pitha PM; Oncology Center, Johns Hopkins University
       School of Medicine,; Baltimore, MD 21231.
 SO    J Interferon Res. 1994 Oct;14(5):259-63. Unique Identifier : AIDSLINE
       MED/95165002
 AB    Recently, we have shown that in acutely infected T cells interferons
       (IFNs) effectively inhibit the human immunodeficiency type 1 (HIV-1)
       proviral DNA synthesis during a single replication cycle. In the present
       study, we have evaluated the relative effectiveness of IFNs in
       restricting HIV-1 expression at post-transcriptional level. Treatment of
       HeLa cells with IFNs A* and B (up to 1,000 U/ml) did not result in a
       reduction in HIV-1 RNA and protein synthesis encoded by the transfected
       HIV-1 proviral clone. Interestingly, IFN treatment reduced significantly
       the HIV-1 mRNA levels encoded by the transfected tat-defective HIV-1
       provirus, and this inhibition could be overcome by transfection with
       Tat- and Rev-expressing plasmids. These results suggest that
       HIV-1-encoded Tat and Rev can overcome the inhibitory effects of IFNs on
       HIV-1 replication.
 DE    Gene Products, tat/*BIOSYNTHESIS  Hela Cells  Human  HIV-1/*DRUG
       EFFECTS/GENETICS  Interferons/*PHARMACOLOGY  RNA Processing,
       Post-Transcriptional  Support, Non-U.S. Gov't  Support, U.S. Gov't,
       P.H.S.  Virus Replication/*DRUG EFFECTS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

